Previous 10 | Next 10 |
Nurix Therapeutics (NRIX): Q4 GAAP EPS of -$0.51 beats by $0.03.Revenue of $6.69M (+259.7% Y/Y) beats by $2.75M.Press Release For further details see: Nurix Therapeutics EPS beats by $0.03, beats on revenue
First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies Three additional wholly owned programs expected to enter clinical trials in 2021 Expanded Sanofi collaboration resulting in option exercise p...
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China's leading e-cigarette brand RLX Technology plans to raise $1.0 billion at a $14.0 billion market cap. Street research is expected for Inhibikase Therape...
The Q4 earnings season cranks up with Procter & Gamble (PG), Netflix (NFLX) and Intel (INTC) some of the more intriguing names to spill numbers. It is week two of trading for Poshmark (POSH) and Petco (WOOF) after huge first day gains were pared a bit on Friday. The economic calendar brin...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Nurix Therapeutics (NRIX) has expanded its global collaboration with Sanofi (SNY) to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas.Sanofi has exercised its option to expand t...
SAN FRANCISCO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of its global strategic collaboration with Sanofi to discover, develop and c...
SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will present a corporate ...
The following slide deck was published by Nurix Therapeutics, Inc. in conjunction with this event. For further details see: Nurix Therapeutics (NRIX) Investor Presentation - Slideshow
The following slide deck was published by Nurix Therapeutics, Inc. in conjunction with this event. For further details see: Nurix Therapeutics (NRIX) Presents At American Society of Hematology Meeting - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...